MGC Pharmaceuticals Limited
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MGCLF research report →
Companymgcpharma.com.au
MGC Pharmaceuticals Limited, a bio-pharma company, develops and supplies phytomedicines in worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia.
- CEO
- Roby Reuven Zomer
- IPO
- 2017
- HQ
- West Perth, WA, AU
Price Chart
Valuation
- Market Cap
- $12.11M
- P/E
- -0.06
- P/S
- 5.44
- P/B
- -0.17
- EV/EBITDA
- -1.37
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 37.96%
- Op Margin
- -457.29%
- Net Margin
- -614.64%
- ROE
- 2660.08%
- ROIC
- -257.29%
Growth & Income
- Revenue
- $3.39M · -28.40%
- Net Income
- $-20,824,000 · -2.34%
- EPS
- $-7.10 · 10.13%
- Op Income
- $-15,493,000
- FCF YoY
- 18.02%
Performance & Tape
- 52W High
- $5.10
- 52W Low
- $0.23
- 50D MA
- $0.27
- 200D MA
- $0.58
- Beta
- 0.97
- Avg Volume
- 192
Get TickerSpark's AI analysis on MGCLF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our MGCLF Coverage
We haven't published any research on MGCLF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MGCLF Report →